

Index

Compiled by Caroline Sheard

- absenteeism and khat use 50
- abstinence from alcohol 64–5
- acamprosate
 - in adolescence 251
 - in alcohol misuse 72, 73, 156, 191
 - in dual diagnosis 209
- ACT in dual diagnosis 178–9
- acupuncture in stimulant misuse 38
- acute confusional state, mushroom-induced 57
- Adams, Tony, *Addicted* 310
- addiction
 - and creativity 306–8
 - and fiction 309–11
 - ICD–10 criteria for 91
 - narratives of 308–9
 - see also specific substances*
- Addiction Severity Index 2
- ADHD 103, 245
- adolescents
 - assessment 242–6, 252–5
 - coping strategies 252
 - dual diagnosis 157, 245–6
 - education, training and employment 250–1
 - effects of parental substance misuse 264
 - family assessment 246
 - first point of contact 242
 - functioning 246
 - gambling 102
 - good practice points 251
 - need for intervention 240–2
 - patterns of substance use 243–5
 - pharmacological therapies 249–50
 - psychological interventions 247–9
 - relapse prevention 251–2
 - screening 242, 252
 - substance misuse 240–58
 - support network 250–1
- Adult Inpatient Care Provision Guidance* 171
- Advisory Council on the Misuse of Drugs 19
- AIDS and Drug Misuse* 17
- alanine aminotransferase 115, 119, 120, 122–3
- alcohol detoxification 61–2, 76–7, 87
 - in adolescence 249
 - and antidepressant use 161, 162, 190–1
 - audit of practice 86–7, 88
 - drug treatment 70–2, 85–6
 - in dual diagnosis 155–6, 208
 - home v. in-patient 61–2, 80
 - preparation for 78–81
 - risk factors in 81
 - service levels 83–5
- Alcohol Problems Questionnaire 61
- alcohol use
 - and cocaine 33
 - controlled drinking 64–5
 - and khat 51
 - legal issues in intoxication 275–87
 - and magic mushrooms 56
- alcohol use disorders 60–1, 72–3
 - abstinence v. controlled drinking 64–5
 - and Alcoholics Anonymous 65
 - and anxiety 163–4, 197, 198, 199–205
 - and bipolar affective disorder 162
 - brief interventions 63–4
 - clinical management 115–16
 - and court proceedings 116
 - and crime 290–3
 - and depression 160–2, 184–95
 - diagnosis 114–15
 - and diminished responsibility 283–5
 - employee assistance programmes 116
 - investigations in diagnosis and management 113–29
 - and literature 303–6
 - and pathological gambling 103

INDEX

- physical disorders associated 127
 in pregnancy 269
 Project MATCH 63, 65–6, 67, 216, 218, 220, 232, 233
 psychological therapies 66–70
 residential therapies 70
 and schizophrenia 159
 screening 114–15, 115–28, 188–90, 204
 self-report 113
 and suicide 185–6
 treatment intensity 62–3
 UKATT 63, 66, 67, 68, 218, 222
 and violence 289–90
 withdrawal syndrome 62, 77–8, 81–2, 197
- Alcohol Use Disorders Identification Test 114–15, 118, 174, 189, 204
- Alcoholics Anonymous 65, 192, 220
 in literature 304, 308, 310
- alkaline phosphatase (ALP) 120, 122
- ALT *see* alanine aminotransferase
- Amanita* 57
- amantadine 37
- amphetamine 26, 29–31
 and anxiety 198
 in breast milk 145
 classification 30
 clinical features of use 33
 and clubbing 32
 complications of use 34, 38–9
 and depression 187, 188
 description 30
 duration of detectability 134
 pharmaceutical 31
 plasma elimination half-life 139
 routes of administration 30, 31
 service levels for users 38
 street price 30
 structure 45
 testing for 137
 use in pregnancy 262–3
see also stimulant misuse
- anaesthetics in khat users 51
- antidepressants
 in adolescence 250
 in alcohol use disorders 161, 162, 190–1
 in anxiety disorder 202, 205, 206, 207
 in opiate dependence 162–3, 190, 191
 in dual diagnosis 209
 in pathological gambling 106, 107
 in stimulant misuse 37, 38
- antipsychotics 158–60
- antisocial personality disorder
 and dual diagnosis 172, 179
 and pathological gambling 103
- anxiety/anxiety disorders
 in adolescence 245
 assessment 204–5
 due to MDMA use 35
 ICD–10 categories 197
 and pathological gambling 103
 and substance misuse 163–4, 196–212
 treatment 205–9
- area under the curve 117, 118
- arrest, drug testing at 295
- arrest referral workers 295
- aspartate aminotransferase (AST) 115, 118, 119, 122–3
 mitochondrial 125
- aspirin, interference with EMIT 133
- assertive community treatment in dual diagnosis 178–9
- assertiveness training 109, 223
- AST *see* aspartate aminotransferase
- attention-deficit hyperactivity disorder 103, 245
- AUC 117, 118
- AUDIT 114–15, 118, 174, 189, 204
- AUDIT-C 115
- automatism as legal defence 285
- aversion therapy 108, 223
- bad trip, magic mushrooms 57
- barbiturates, duration of detectability 134
- Baudelaire, Charles 304
- Behan, Brendan 306
- behavioural couples therapy 221–2
- behavioural monitoring 108
- behavioural skills training 67
- behavioural therapy
 anxiety disorder 206, 207
 in dual diagnosis 179–80
 pathological gambling 108
- benzodiazepines
 in alcohol detoxification 85–6, 249
 in anxiety disorder 202, 206, 206–7
 dependence 164, 250, 268–9
 in dual diagnosis 209
 duration of detectability 134
 potential for misuse 38
 use in pregnancy 263, 268–9
 withdrawal syndrome 197–8
- benzoylecgonine 134, 139
- beta-blockers in anxiety disorder 207
- beta-hexosaminidase 125
- biographical perspectives on addiction 303–14
- bipolar affective disorder 162, 179

- blood
 drug testing 138–40
 ethanol concentration testing 121, 122
 monitoring drug levels in maintenance therapy 138–40, 141
- bombing 31
- Brain Reports 16, 19
- breastfeeding
 and drug testing 144–5
 and smoking cessation 156, 158
 and substance misuse 269–70
- breath testing
 alcohol 115–16, 121, 122
 drugs 143
- brief interventions in alcohol use disorders 63–4
- British Gambling Prevalence Survey 101, 102
- British system, evolution of 14–20
- bromocriptine 37
- Bukowski, Charles 305–6
- Bulgakov, Mikhail 312
- buprenorphine
 in adolescent opiate dependence 250
 in dual diagnosis 157
 duration of detectability 134
 maintenance treatment 2, 3, 11
 in opiate detoxification 4, 5
 plasma elimination half-life 139
 in pregnancy 268
 and stimulant use 37
 testing for 144
- bupropion
 in pathological gambling 107
 in smoking cessation 95, 98, 156
- Burgess, Melvin, *Junk* 310
- Burroughs, William S. 308, 309, 310, 311, 312
- Burroughs, William S. Jr 311
- buspirone
 in anxiety disorder 202, 207
 in dual diagnosis 209
- C-BIT 216
- caffeine and anxiety 198
- CAGE questionnaire 114, 189
- Caldwell-type recklessness 280–1
- cannabis
 and anxiety 198
 in dual diagnosis 157, 159
 duration of detectability 134
 and khat 51
 and magic mushrooms 56
 passive exposure to 135
 plasma elimination half-life 139
 testing for 136, 137, 140, 143
- CARAT initiatives 18, 295, 296
- carbamazepine
 in alcohol detoxification 86, 156
 in pathological gambling 107
- carbohydrate-deficient transferrin 115, 118, 119, 120, 124, 125, 189
- cardiovascular disease and nicotine replacement therapy 97–8
- care plans 23
- care programme approach 31
- Catha edulis* (cat) *see* khat
- cathidine 45
- cathine 43, 45–6
- cathinone 43, 45–6
- CBT *see* cognitive-behavioural therapy
- CDT 115, 118, 119, 120, 124, 125, 189
- chain of custody procedures, and drug testing 130–1
- change
 models of health behaviour change 234–5
 resistance to 236
 stages of change model 79, 247
 transtheoretical model of 235
- chat *see* khat
- Chemical Use, Abuse and Dependence scale 173, 174
- chewing-gum, nicotine 95
- children
 effects of parental substance misuse 260, 261
 long-term effects of maternal substance misuse 263–4
 protection of 270–1
- chlordiazepoxide 61, 84, 85, 134, 155
- chlormethiazole 86
- cigarettes *see* smoking
- citalopram
 in panic disorder 205
 in pathological gambling 106
- CIWA–Ar scale 155
- CJITs 295
- cleft lip/palate 263
- Clinical Institute Withdrawal Assessment for Alcohol scale 155
- clomipramine
 in obsessive-compulsive disorder 207
 in panic disorder 205
- clonazepam 206, 207
- clonidine 4–5, 157, 250
- clozapine 158–9
- clubbing 32
- cocaine 29–31
 in adolescence 250
 and alcohol use 33

INDEX

- and anxiety 198
- in breast milk 145
- classification 30
- clinical features of use 33
- and depression 163, 187, 188
- description 30
- duration of detectability 134
- and khat use 51
- maintenance treatment 37–8
- plasma elimination half-life 139
- psychosocial treatment 37
- routes of administration 30, 31
- street price 30
- testing for 136, 137
- use in pregnancy 262–3, 268
- codeine
 - duration of detectability 134
 - metabolites 133
 - plasma elimination half-life 139
- ‘co-dependence’ stories 309
- cognitive–behavioural integrated treatment 216
- cognitive–behavioural therapy (CBT)
 - 215–16
 - adolescent substance misuse 247, 252
 - alcohol misuse 67
 - anxiety disorder 206, 207
 - drug dependence 8–9
 - in dual diagnosis 179, 208–9
 - group 249
 - pathological gambling 109
 - stimulant misuse 36, 37
- cognitive deficits due to MDMA use 35
- cognitive therapy
 - anxiety disorder 206, 207
 - in dual diagnosis 192
 - pathological gambling 108–9
- Coleridge, Samuel Taylor, *Kubla Khan* 306–7
- Collins, Wilkie, *The Moonstone* 307, 308
- Combined Psychosis and Substance Use programme 179
- come-down 32
- communication skills training 219
- community drug teams 17
- community reinforcement 218–19
 - in alcohol misuse 68
 - in drug dependence 10
 - in dual diagnosis 192
 - in stimulant misuse 37
- community reinforcement and family training 221
- comorbidity *see* dual diagnosis
- COMPASS 179
- complementary therapies 38
- conditional cautioning targets 295
- conduct disorder 245
- contingency management 219–20
 - alcohol use disorders 68–9
 - in maintenance treatment 3–4
 - principal components 69
- coping strategies
 - adolescents 252
 - in substance misuse 153
 - training 36
- cotinine 92
- counselling 222–3
 - in adolescent substance misuse 247
 - in stimulant misuse 36–7
- couple therapy 10
- court proceedings in alcohol use disorders 116
- covert desensitisation in pathological gambling 108
- CPA 31
- crack cocaine 26, 29–30
 - classification 30
 - complications of use 34
 - description 30
 - routes of administration 30, 31
 - street price 30
- CRAFT 221
- crash 32
- Crime and Disorder Act 1998 11
- crime reduction agenda 17–19
- Criminal Justice Act 1967 279–80
- criminal justice integrated teams 295
- criminal offences
 - of basic intent 277, 278, 280–1
 - and intoxication 275–87
 - and recklessness 280–1
 - of specific intent 277, 278, 279–80
 - and substance misuse 290–3
- CUAD 173, 174
- cue exposure 69–70, 223
- cyclobarbitone 134
- Dartmouth Assessment of Lifestyle Instrument (DALI) 173, 174
- DAST-10 174
- De Quincey, Thomas 307–8
- dehydration due to MDMA use 35
- delirium in alcohol withdrawal 77
- depression
 - in adolescence 245
 - associated with khat use 47, 49
 - due to MDMA use 35
 - and pathological gambling 103
 - post-intoxication 187
 - and substance misuse 160–3, 184–95

- desensitisation in pathological gambling 108
- desipramine
 in adolescence 250
 in alcohol use disorders 161, 191
 in stimulant use 38
- dexamphetamine 38
- dialectical behavioural therapy 179–80
- diazepam
 in alcohol detoxification 85, 155
 duration of detectability 134
 plasma elimination half-life 139
- dihydrocodeine
 duration of detectability 134
 plasma elimination half-life 139
- diminished responsibility as legal defence 283–5
- disseminated intravascular coagulation due to MDMA use 35
- district drug advisory committees 17
- disulfiram 37–8, 70–1, 156, 191
- divorce and khat use 51
- doctors, as viewed by patients 312–13
- dopamine
 and khat use 46
 and motivational states 158
 and nicotine addiction 93
- Drinker's Check-Up 232
- DRRs 295
- Drug Abuse Screening Test 174
- drug action teams 18, 21–2
- drug dependency units 16
- Drug Intervention Programme 18–19, 20, 294, 295
- drug rehabilitation requirements 295
- drug testing *see* screening
- drug treatment and testing orders 11, 18
- 'drugs czar' 18
- DTTOs 11, 18
- dual diagnosis 149, 165–6, 169–70
 in adolescence 157, 245–6
 alternative terminology 150
 anxiety and substance misuse 163–4, 196–212
 assessment 172–4, 188–90, 204–5
 clinical trial shortcomings 165
 co-morbidity in pathological gambling 103, 104–5
 and crime 292–3
 definition 149–50, 172
 depression and substance misuse 160–3, 184–95
 distinction between primary and substance-induced psychiatric comorbidity 172, 186–8
- epidemiology 150–1, 169, 185–6
 and forensic psychiatry 288–9
 monitoring interventions 164–5
 optimal services 180–1, 194
 policy context 151–2, 170–2
 prognosis 192–3
 self-medication hypothesis 172, 187, 199, 200
 service provision 193, 194
 in stimulant misuse 31, 39–40
 supersensitivity model 172
 treatment
 considerations 176–7
 efficacy and cost-effectiveness 152
 evaluation 178–80
 integrated 175
 models 174–6
 parallel 175
 pharmacological 154–68, 190–1, 209
 potential interventions 177–8
 principles 176
 of psychiatric disorder 158–64
 psychological 152–4, 177–80, 191–2, 208–9
 psychosocial context 152–4, 169–83
 serial 175
 of substance misuse 154–8
 and violence 292–3, 296–8, 299
- Dual Diagnosis Good Practice Guide* 152, 170–1
- eating disorders 245
- ECA study 185, 288–9
- ecstasy *see* MDMA
- eduline 45
- effect size 2
- ELISA 136
- EMIT 132, 133
- employee assistance programmes in alcohol use disorders 116
- enabling behaviour in adolescent substance misuse 246
- enzyme-linked immunosorbent assay 136
- enzyme-mediated immunoassay technique 132, 133
- ephedrine 45
- Epidemiologic Catchment Area Study 185, 288–9
- erythrocyte aldehyde dehydrogenase 125
- escitalopram 205
- ethanol, measurement methods 118–19, 121–2
- ethylglucuronide 125
- exposure therapy in anxiety disorder 207
- eye movement desensitisation and reprocessing 206

INDEX

- Fallon Inquiry 300
 false negatives/false positives in drug testing 133–5
 family assessment in adolescent substance misuse 246
 family education in stimulant misuse 37
 family life and khat use 50–1
 family therapy 220–2
 adolescent substance misuse 247–9
 drug dependence 10
 in dual diagnosis 179
 multidimensional 248–9
 Fast Alcohol Screening Test (FAST) 115
 fatty acid esters 125
 Faulkner, William 304
 ‘first drink of the day’ test 284
 Fitzgerald, F. Scott 304, 305, 306, 312
 flashbacks due to MDMA use 35
 floppy baby syndrome 263
 flunitrazepam 139
 fluoxetine 106, 162, 163, 190, 191, 207, 250
 flupentixol 160
 fluvoxamine 106, 207
 foetal alcohol syndrome 269
 foetus, effects of maternal drug use 261–3, 269
 forensic psychiatry 288–9
 assessment of substance misuse 293–4
 decision-making and liaison 294–6
 referral 296
 scope and limitations 293–6
- GA-20 105
 GABA-ergic system
 and alcohol use 85, 163, 201
 and anxiety 163, 201
- Gamblers Anonymous 108, 109–10
 GA-20 105
- gambling, pathological 101, 110
 adverse consequences 102
 aetiology 105
 assessment 103–5
 diagnostic criteria 103–4
 epidemiology 102
 pharmacological therapy 106–8
 psychiatric comorbidity 103, 104–5
 psychological interventions 108–10
- gamma glutamyltransferase 115, 118, 119, 120, 122–3, 125, 189
 gas chromatography 132
 general practitioners (GPs)
 role in drug dependence treatment 19–20
 role in smoking cessation 93, 99
 with special interest 20
 generalised anxiety disorder 197, 207
- GGT 115, 118, 119, 120, 122–3, 125, 189
 GPs *see* general practitioners
 GPwSIs 20
 group therapy
 adolescent substance misuse 249
 in dual diagnosis 179, 192
 stimulant misuse 37
- hair
 analysis in dual diagnosis 172
 decontamination 142
 drug testing 36, 135, 140, 142
 sample collection 142
- hallucinations in alcohol withdrawal 78
 harm reduction 16–17, 36, 38
 HDL and alcohol consumption 125
 health behaviour change, models of 234–5
 Hemingway, Ernest 304
 hepatitis C 34
 heroin
 association with khat use 51
 metabolites 133
 plasma elimination half-life 139
 testing for 132, 136
 see also opiate dependence
- high-density lipoproteins and alcohol consumption 125
- homicide
 and dual diagnosis 169
 and substance misuse 292–3
- housing for dual diagnosis patients 181
 5-HT *see* serotonergic system
 5-HTOL:5-HIAA ratio 125
 Huxley, Aldous, *The Doors of Perception* 310
 hyperthermia due to MDMA use 35
- ice 31
 IDTS 294
 imaginal desensitisation 108
 imaginal relaxation 108
 imipramine
 in alcohol use disorders 161
 in anxiety disorder 207
 in dual diagnosis 209
 in opiate dependence 162–3
- immigrants, khat use 44–5
 immunoassay, interpretation 135
 impulse-control disorders 103
 inhalant misuse and anxiety 198
 inhalators, nicotine 96
 insanity as legal defence 279, 283
 integrated drug treatment system 294
 Interim Analytical Report of the National Alcohol Harm Reduction Strategy 291
 interpersonal group psychotherapy 249

- intoxicated belief as a defence 282
 intoxication
 and crimes of basic intent 277, 278, 280–1
 and crimes of specific intent 277, 278, 279–80
 and diminished responsibility 283–4
 drug-induced 281
 and Dutch courage 282
 involuntary 278–9
 legal aspects 275–87
 legal defences available 286
 and mental health defences 282–5
 and mistake 281–2
 partial 281
 and rape 281
 voluntary 277–8, 279–81
- jaad *see* khat
- Kerouac, Jack 305, 306, 308
 ketamine 32
 khat 42
 association with alcohol, tobacco and drug use 51
 dependence 46
 effects of long-term use 49–51
 effects of 44
 epidemiology of use 44–5
 history of use 42–4
 ingestion methods 43
 interaction with prescription medicines 51
 legal aspects of use 43
 pharmacokinetics 46–7
 pharmacology 45–6
 physical adverse effects 49–50
 psychiatric sequelae 47–9, 52–3
 reasons for use 44
 screening for 51–2
 withdrawal syndrome 47, 49
- King, Stephen 304
 Knapp, Caroline, *Drinking: A Love Story* 310
- L-alpha-acetylmethadol (LAAM) 5
 laboratory reference ranges 120
 laudanum 306, 307
 legal issues in intoxication 275–87
 Lewis, Sinclair 304
 liberty cap mushroom 55–9
 Lie/Bet Questionnaire 105
 life events and adolescent substance misuse 245
 liquid chromatography 132
 literary perspectives 303–14
- lithium 107
 liver enzyme tests 115, 118, 119, 120, 122–3, 125
 lofexidine 3, 4–5, 157, 203, 250
 ‘love’ stories 309
 Lowry, Malcolm 305, 306
 lozenges, nicotine 96
 LSD (lysergic acid diethylamide)
 and anxiety 198
 and clubbing 32
 duration of detectability 134
 and magic mushrooms 57
 and synaesthesia 56
- MacArthur Violence Risk Assessment Study 292
 magic mushrooms 55, 58–9
 adverse effects 56–7
 desired effects 56
 management of use 58
 possible ICD-10 diagnoses 58
 screening 57
 usage 55–6
- mairungi *see* khat
 MAM 132, 133
 mania associated with khat use 47, 48–9
 Marlowe, Ann, *How to Stop Time: Heroin from A to Z* 310
 mass spectrometry 132
 MAST 114
 ‘mastery’ stories 309
 MCV 115, 118, 119, 120, 123–4, 125, 189
 MDA 32
 MDEA 32
 MDMA 29–30
 classification 30
 clinical features of use 33
 complications of use 35
 depression following use 187
 description 30
 duration of detectability 134
 plasma elimination half-life 139
 routes of administration 30, 32
 street price 30
 testing for 144
 treatment 38
- mean cell volume 115, 118, 119, 120, 123–4, 125, 189
 meconium, drug testing 145
 mental health defences 279, 282–5
 methadone
 in adolescent opiate dependence 250
 and antidepressant use 191
 and anxiety 200
 and breastfeeding 145

INDEX

- and cocaine use 37
- detoxification treatment 4, 5
- duration of detectability 134
- maintenance treatment 2–3, 11, 16, 157
- metabolites 137
- neonatal withdrawal syndrome 158, 261–2, 265–6
- number of prescriptions 26
- parenteral 6
- plasma concentration measurement 139–40, 141
- plasma elimination half-life 139
- in pregnancy 158, 261–2, 265–6, 266–8
- sweat testing 144
- methamphetamine 31, 134
- methaqualone 134
- 3,4-methylenedioxyamphetamine 32
- 3,4-methylenedioxyethylamphetamine 32
- methylenedioxyamphetamine *see* MDMA
- methylphenidate 38
- Michigan Alcoholism Screening Test 114
- Mini-Mental State Examination 174
- miraa *see* khat
- mirtazapine 202
- Misuse of Drugs Act 1971 29, 30, 55
- MMSE 174
- M’Naghten rules 283, 285
- Models of Care for Alcohol Misusers 77, 83
- Models of Care for Treatment of Adult Drug Misusers 20–5, 171, 181
- 6-monoacetylmorphine 132, 133
- monoamine oxidase inhibitors
 - in anxiety disorder 202, 205, 206
 - interaction with khat 51
- mood disorders 160–4
- morphine
 - duration of detectability 134
 - as metabolite 133
 - plasma elimination half-life 139
 - testing for 136, 137
 - urinary, potential sources 135
- motivational enhancement 218
 - in adolescent substance misuse 247
 - in alcohol misuse 66–7
 - in drug dependence 9
 - in dual diagnosis 192
- motivational interviewing 217–18, 229–39
 - in adolescent substance misuse 247, 248
 - central principles 230
 - in drug dependence 9, 11
 - in dual diagnosis 179
 - effective implementation 234
 - evidence base 231–3
 - FRAMES formulation 66
 - in stimulant misuse 36
- Motivational Interviewing Skill Code 233
- Motivational Interviewing Treatment Integrity 233
- mushrooms
 - magic 55–9
 - poisonous 57
- myocardial infarction due to stimulant use 33–4
- naloxone 5, 157
- naltrexone
 - in adolescent alcohol misuse 251–2
 - in adolescent opiate dependence 250
 - in alcohol misuse 71–2, 73, 156, 191
 - in drug dependence 3, 5, 157
 - in pathological gambling 106–7
- Narcotics Anonymous 7, 8, 192, 220
- nasal spray, nicotine 96
- National Minimum Standards for Psychiatric Intensive Care Units and Low Secure Environments* 171
- National Service Framework for Mental Health 170
- National Treatment Agency for Substance Misuse 18, 25–6
- National Treatment Outcome Research Study 18
- needle exchange programmes 6, 11, 17
- nefazodone
 - in depression with opiate dependence 163
 - in pathological gambling 107
- negative predictive value 117
- neonatal abstinence syndromes 158, 261–2, 265–6
- neonates, effects of maternal substance misuse 158, 259–63, 265–6
- neuro-linguistic programming 223
- NHS Plan 19–20
- nicotine
 - addictive properties 91–2
 - and anxiety 198
 - passive exposure to 135
 - pharmacology in tobacco smoke 92–3
 - replacement therapy 95–8, 156–7
 - tolerance to 92
 - withdrawal syndrome 91–2, 98
- Nietzsche, Friedrich 304
- nitrazepam
 - duration of detectability 134
 - plasma elimination half-life 139
- NMDA receptors, and alcohol use 85

- noradrenergic system 163
 and comorbid anxiety and alcohol misuse 203
 and khat use 46
 nordiazepam 139
 norpropoxyphene 134
 NPV 117
 NTA 18, 25–6
- obsessive–compulsive disorder (OCD) 197, 207
 olanzapine 86, 107, 160
 O'Neill, Eugene 304, 312
 opiate dependence
 in adolescence 250
 and anxiety 198
 and depression 162–3, 184–95
 detoxification 4–6
 in dual diagnosis 157, 162–3
 injectable treatment 6
 maintenance treatment 2–4, 11, 16, 139–40, 141, 157
 pharmacotherapy 2–4
 in pregnancy 158, 261–2, 266–8
 psychological therapies 6–11
 testing for 132, 136
 opium and creativity 306–8
 oppositional defiant disorder 245
 Orange Guidelines 26
 oxazepam 62, 133
- Paddington Alcohol Test 115, 189
 panic attacks 204
 panic disorder 197, 199, 200, 201, 205–6
 parenting
 and substance misuse 260, 261
 training 270
 paroxetine
 in anxiety disorder 206, 207
 in panic disorder 205
 in pathological gambling 106
 PAT 115, 189
 PCP
 and anxiety 198
 duration of detectability 134
 pentobarbitone 134
 'personal growth' stories 309
 personality disorder 58
 and dual diagnosis 172, 179–80
 guidelines 171–2
 and pathological gambling 103
Personality Disorder: No Longer a Diagnosis of Exclusion 171–2
 Pharmacy Act 1868 15
- phencyclidine *see* PCP
 phenobarbitone 134
 phenylpropanolamine 51
 phobic disorder 197, 200, 207
 phosphatidylethanol 125
 poppy seed defence 135
 positive predictive value 117
 post-traumatic stress disorder 206
 PPV 117
 pregabalin 202, 207
 pregnancy
 alcohol use disorders 269
 amphetamine use 262–3
 assessment 265
 benzodiazepine use 263, 268–9
 blood-borne viral infections 263
 cocaine use 262–3, 268
 dual diagnosis in 157–8
 effects of drug use on child 260–4
 effects of drug use on mother 260
 epidemiology of drug use 259
 management plan formulation 264–6
 opiate dependence in 158, 261–2, 266–8
 outcome of treatment 271
 pharmacological therapies 266–9
 psychosocial issues 270–1
 smoking cessation in 98, 156, 158
 treatment setting 271–2
 use of stimulants in 33
 PRISM 173, 174
 prison, therapy in 296
 prisoners, prescribing for 158
 problem-solving training 109, 219
 Project MATCH 63, 65–6, 67, 216, 218, 220, 232, 233
 propoxyphene 134
 pseudoephedrine 135
Psilocybe semilanceata 55–9
 psilocybin 55, 57
 Psychiatric Research Interview for Substance and Mental Disorders 173, 174
 psychiatric sequelae of stimulant use 31, 33, 34–5, 38–9
 psychodynamic psychotherapy 9
 psychological interventions 213–14, 224
 in adolescence 247–9
 alcohol use disorders 66–70
 in dual diagnosis 152–4, 177–80, 191–2, 208–9
 effectiveness 214–15
 opiate dependence 6–11
 pathological gambling 108–10
 stimulant misuse 36–7
 see also specific techniques

INDEX

- psychosis
 drug-induced 31, 33, 34–5, 38–9
 in dual diagnosis 158–60, 172, 179
 khat-induced 47, 48–9, 52–3
 mushroom-induced 57
 psychosocial support in smoking cessation 96
- qaad/qat *see* khat
- quality standards for service provision in
 dual diagnosis 180
- quetiapine 163
- rape and intoxication 281
- reboxetine 202
- receiver operating characteristic curve 117, 118
- recklessness 280–1
- recovering alcoholics 64
- rehabilitation units, residential
 in alcohol misuse 70, 84–5
 in drug dependence 10
- reinforcement techniques in drug
 dependence 10
- relapse prevention therapy 216–17
 drug dependence 8
 pathological gambling 109
- relaxation training 67–8
- renal failure due to MDMA use 35
- resistance to change 236
- restriction on bail 295
- reversible monoamine oxidase inhibitors 205, 206
- reward pathway 32
- rhabdomyolysis due to MDMA use 35
- RIMAs 205, 206
- risk assessment with violent offenders 296–8
- RoB 295
- ROC curve 117, 118
- Rolleston Report 15–16
- Roth, Joseph, *The Legend of the Holy Drinker* 309
- SADQ 155
- saliva
 drug testing 142–3
 ethanol concentration testing 121
- SASQ 115
- SATS 173, 174
- SBNT 68, 222
- schizoaffective disorder 158–60
- schizophrenia 158–60, 172
- Scotland, legal system 276
- Scott, Sir Walter, *The Bride of Lammermoor* 307, 308
- screening 2, 130
 adolescents 242, 252
 alcohol use disorders 114–15, 115–28, 188–90, 204
 blood 121, 122, 138–40, 141
 breast milk 144–5
 breath analysis 115–16, 121, 122, 143
 and chain of custody procedures 130–1
 choice of test 132
 drug use 130–48
 in dual diagnosis 172–4, 188–90, 204–5
 hair 36, 135, 140, 142, 172
 interpretation 133–5
 khat 51–2
 legal and ethical issues 131
 magic mushrooms 57
 meconium 145
 policy agreement 131
 rationale 131–2
 routine 132–3
 saliva 121, 142–3
 self-contained kits 136
 stimulant misuse 35–6
 sweat 121, 144
 urine 35–6, 51–2, 121, 136–7, 172
- secure psychiatric units, substance misuse in 299–300
- seizures, in alcohol withdrawal 77, 78
- Selby, Hubert Jr 311, 312
- selective serotonin reuptake inhibitors (SSRIs)
 in alcohol use disorders 161, 162
 in anxiety disorder 202, 205, 206, 207
 in dual diagnosis 209
 in opiate dependence 163, 191
 in pathological gambling 106, 107
- Self, Will 308
- self-harm
 associated with khat use 47, 49
 and suicide 186
- sensitive anticipatory action 164–5
- sensitivity, definition 116
- serotonergic system
 and alcohol use 163, 202–3
 and anxiety 163, 202–3
 and dual diagnosis 188
 and khat use 46
 and pathological gambling 106
 and violent behaviour 290
- sertraline
 in anxiety disorder 206, 207
 in pathological gambling 106

- services
 alcohol detoxification 83–5
 context and provision 20–5
 development 14–20
 dual diagnosis 180–1, 193, 194
 National Service Framework for Mental Health 170
 reviews 25–6
 Task Force to Review Services for Drug Misusers 17
 Severity of Alcohol Dependence Questionnaire 155
 shared care 20
 Shell, Ray, *Iced* 310
 Shelley, Mary, *Frankenstein* 307
 sialic acid 125
 Simenon, Georges 304
 Single Alcohol Screening Question 115
 SMAQ 242, 252
 smoking 90
 cessation programmes 92, 93–9
 in dual diagnosis 156–7
 and khat use 51
 and nicotine addiction 91–2
 pharmacology of nicotine in tobacco smoke 92–3
 and schizophrenia 159
 sobriety sampling 219
 social anxiety disorder 197, 200, 206–7
 social behaviour and network therapy 68, 222
 social skills training
 in alcohol misuse 67–8
 in pathological gambling 109
 social support groups, in stimulant misuse 37
 South Oaks Gambling Screen 105
 specificity, definition 117
 speed 31
 spousal contingency contracting 108
 SSRIs *see* selective serotonin reuptake inhibitors
 Steinbeck, John 304
 stimulant misuse 29–32
 assessment 35–6
 clinical features 32–3
 complications 33–5
 dual diagnosis 31, 39–40, 157, 187, 188, 198
 management 35–40
 in pregnancy 33
 screening for 35–6
 withdrawal syndrome 32–3
 stroke due to stimulant use 33–4
 Suboxone 5
 Substance Abuse Treatment Scale 173, 174
 substance dependence, definition 1
 substance misuse, definition 1
see also specific substances
 Substance Misuse in Adolescence Questionnaire 242, 252
 suicide
 in adolescence 245
 and alcohol use disorders 185–6
 and dual diagnosis 169, 185–6
 and khat use 49
 and pathological gambling 103, 105
 and self-harm 186
 Sutherland, John, *Last Drink to LA* 303–4
 sweat
 drug testing 144
 ethanol concentration testing 121
 synaesthesia
 and LSD 56
 and magic mushrooms 56

Tackling Drugs to Build a Better Britain 18, 19, 26
Tackling Drugs Together: A Strategy for England 19
 tannin in khat 45
 Task Force to Review Services for Drug Misusers 17
 temazepam
 duration of detectability 134
 plasma elimination half-life 139
 tetrahydrocannabinol (THC) 143, 145
 therapeutic communities 223
 in alcohol misuse 70
 in drug dependence 10
 thiamine 86, 155–6
 Thomas, Dylan 306
 topiramate 107
 transdermal nicotine patches 96
 transtheoretical model of change 235
 trazodone 202, 206, 207
 treatment journey 23, 24, 25
 tremor, in alcohol withdrawal 77
 triazolam 134
 tricyclic antidepressants
 in alcohol use disorders 161
 in anxiety disorder 202
 in opiate dependence 162–3, 191
 trip, magic mushrooms 56, 57
 true negative/positive rates 117
 Twelve-Step Approach 7, 8, 65, 67, 110, 175, 220, 249

 INDEX

- UK Alcohol Treatment Trial (UKATT) 63, 66, 67, 68, 218, 222
- UK Anti-Drug Co-ordination Unit (UKADCU) 18
- ultra-rapid opiate detoxification 5–6
- unemployment and khat use 50
- urine
 - analysis in dual diagnosis 172
 - chain of custody procedures for samples 130–1, 137
 - checking validity of samples 137
 - drug testing 136–7
 - ethanol concentration testing 121
 - testing for khat use 51–2
 - testing for stimulant misuse 35–6
- valproate
 - in alcohol use disorders 162
 - in pathological gambling 107
- varenicline 95
- venlafaxine 202, 207
- Verghese, Abraham 312–13
- violence
 - associated with khat use 47, 49
 - and dual diagnosis 292–3, 296–8, 299
 - management 296–8
 - risk assessment 296–8
 - and substance misuse 289–90
- viral infection, transmission from mother to child 263
- vitamin B 156
- Welsh, Irvine, *Trainspotting* 309
- Wernicke's encephalopathy 86, 155
- whizz 31
- Windsor Clinic Alcohol Withdrawal Scale 82
- withdrawal syndromes
 - alcohol misuse 62, 77–8, 81–2, 197
 - benzodiazepines 197–8
 - khat 47, 49
 - neonatal 158, 261–2, 265–6
 - nicotine 91–2, 98
 - stimulants 32–3